{"protocolSection": {"identificationModule": {"nctId": "NCT01483560", "orgStudyIdInfo": {"id": "GN10DI406"}, "secondaryIdInfos": [{"id": "2011-000300-18", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "University of Glasgow", "class": "OTHER"}, "briefTitle": "REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)", "officialTitle": "Phase 3 Study of Metformin in Adults With Type 1 Diabetes", "acronym": "REMOVAL"}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-12"}, "primaryCompletionDateStruct": {"date": "2017-03-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-11-23", "studyFirstSubmitQcDate": "2011-11-30", "studyFirstPostDateStruct": {"date": "2011-12-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-09-20", "resultsFirstSubmitQcDate": "2019-02-18", "resultsFirstPostDateStruct": {"date": "2019-06-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-04", "lastUpdatePostDateStruct": {"date": "2019-06-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Prof John Petrie", "investigatorTitle": "Clinical Professor in Diabetic Medicine", "investigatorAffiliation": "University of Glasgow"}, "leadSponsor": {"name": "University of Glasgow", "class": "OTHER"}, "collaborators": [{"name": "NHS Greater Glasgow and Clyde", "class": "OTHER"}, {"name": "Juvenile Diabetes Research Foundation", "class": "OTHER"}, {"name": "Imperial College London", "class": "OTHER"}, {"name": "University of Wisconsin, Madison", "class": "OTHER"}, {"name": "University of Dundee", "class": "OTHER"}, {"name": "Merck Serono S.A., Geneva", "class": "INDUSTRY"}, {"name": "Itamar-Medical, Israel", "class": "INDUSTRY"}, {"name": "University of Western Ontario, Canada", "class": "OTHER"}, {"name": "University of Melbourne", "class": "OTHER"}, {"name": "Steno Diabetes Center Copenhagen", "class": "OTHER"}, {"name": "Maastricht University Medical Center", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 1"], "keywords": ["REMOVAL", "metformin", "carotid IMT", "LDL Cholesterol", "endothelial function", "retinopathy", "HbA1c"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 493, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin", "type": "EXPERIMENTAL", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily", "interventionNames": ["Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "3 years treatment duration", "armGroupLabels": ["Metformin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Placebo", "description": "3 years duration", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)", "description": "Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.", "timeFrame": "0, 12 months, 24 months, 36 months"}], "secondaryOutcomes": [{"measure": "Change in HbA1c", "description": "Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.", "timeFrame": "Baseline, Year 3"}, {"measure": "Change in LDL Cholesterol", "description": "mmol/L Centrally assayed at the University of Glasgow", "timeFrame": "Baseline, Year 3"}, {"measure": "Change in Estimated Glomerular Filtration Rate", "description": "Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories", "timeFrame": "Baseline, Year 1, Year 2, Year 3"}, {"measure": "Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months", "description": "Two color 45\u00b0 field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.", "timeFrame": "Baseline, Year 3"}, {"measure": "Change in Weight", "description": "Measured at sites using calibrated weighing scales", "timeFrame": "Baseline, Year 1, Year 2, Year 3"}, {"measure": "Change in Insulin Dose", "description": "Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields", "timeFrame": "Baseline, Year 1, Year 2, Year 3"}, {"measure": "Change in Endothelial Function", "description": "In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)", "timeFrame": "Baseline, Year 1, Year 3"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 1 Diabetes for five years or more\\*\n* Age 40 years or above\n* 7.0 =\\< HbA1c \\<10.0% (53 - 86 mmol/mol)\n\nAND 3 or more of the following ten CardioVascular Disease (CVD) risk factors:\n\n* BMI \\>27 kg/m\\^2\n* Current HbA1c \\>8.0% (64 mmol/mol)\n* Known CVD/peripheral vascular disease\n* Current smoker\n* Estimated glomerular filtration rate (eGFR) \\<90 ml/min per 1.73 m\\^3\n* Confirmed micro- or macroalbuminuria \\[according to local assays and reference ranges\\]\n* Hypertension (BP \\>=140/90 millimeters of mercury (mmHg) or established on antihypertensive treatment)\n* Dyslipidaemia \\[total cholesterol \\>=5.0 mmol/L (200 mg/dL);OR HDL cholesterol \\<1.20 mmol/L (46mg/dL) \\[MEN\\]; OR \\<1.30 mmol/L (50 mg/dL) \\[WOMEN\\]; or triglycerides \\>=1.7 mmol/L (150mg/dL); or established on lipid-lowering treatment)\\]\n* Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling with myocardial infarction or stroke aged \\<60 years)\n* Duration of diabetes \\> 20 years\n\nExclusion Criteria:\n\n* eGFR \\< 45 ml/min/1.73m2\n* woman of childbearing age not on effective contraception\n* Pregnancy and/or lactation\n* Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months\n* NYHA stage 3 or 4 heart failure\n* Significant hypoglycaemia unawareness\n* Impaired cognitive function/ unable to give informed consent\n* Previous carotid surgery/ inability to capture adequate carotid images\n* Estimated glomerular filtration \\< 45ml/min/1.73m\\^2 (MDRD)\n* Gastroparesis\n* History of lactic acidosis\n* Other contraindications to metformin (hepatic impairment, known hypersensitivity to metformin, acute illness such as dehydration, severe infection, shock, acute cardiac failure or suspected tissue hypoxia)\n* Any coexistent life threatening condition including prior diagnosis of cancer within two years\n* History of alcohol problem or drug abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "John Petrie, Prof", "affiliation": "University of Glasgow", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Helen Colhoun, Prof", "affiliation": "University of Dundee", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Royal Melbourne Hospital", "city": "Melbourne", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "St Vincent's Hospital", "city": "Melbourne", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "Royal Prince Albert Hospital", "city": "Sydney", "country": "Australia", "geoPoint": {"lat": -33.86785, "lon": 151.20732}}, {"facility": "St Joseph's Health Care", "city": "London", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Ottawa Hospital Riverside Campus", "city": "Ottawa", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Steno Diabetes Centre", "city": "Gentofte", "country": "Denmark", "geoPoint": {"lat": 55.74903, "lon": 12.54601}}, {"facility": "Maastricht University Medical Centre", "city": "Maastricht", "country": "Netherlands", "geoPoint": {"lat": 50.84833, "lon": 5.68889}}, {"facility": "Aberdeen Royal Infirmary", "city": "Aberdeen", "country": "United Kingdom", "geoPoint": {"lat": 57.14369, "lon": -2.09814}}, {"facility": "Ayr Hospital", "city": "Ayr", "zip": "KA6 6DX", "country": "United Kingdom", "geoPoint": {"lat": 55.46273, "lon": -4.63393}}, {"facility": "University Hospitals Bristol", "city": "Bristol", "zip": "BS2 8HW", "country": "United Kingdom", "geoPoint": {"lat": 51.45523, "lon": -2.59665}}, {"facility": "Diabetes Support Unit, Ninewells Hospital and Medical School", "city": "Dundee", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "University Hospital North Durham", "city": "Durham", "country": "United Kingdom", "geoPoint": {"lat": 54.77676, "lon": -1.57566}}, {"facility": "Edinburgh Royal Infirmary", "city": "Edinburgh", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Edinburgh Western Infirmary", "city": "Edinburgh", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust", "city": "Exeter", "country": "United Kingdom", "geoPoint": {"lat": 50.7236, "lon": -3.52751}}, {"facility": "Stobhill Hospital, Diabetes Clinic", "city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Gloucestershire Royal Hospital", "city": "Gloucester", "zip": "GL1 3NN", "country": "United Kingdom", "geoPoint": {"lat": 51.86568, "lon": -2.2431}}, {"facility": "Michael White Diabetes Centre, Hull Royal Infirmary", "city": "Hull", "country": "United Kingdom", "geoPoint": {"lat": 53.7446, "lon": -0.33525}}, {"facility": "Clinical Sciences Centre, University Hospital", "city": "Liverpool", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital", "city": "Newcastle", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "Diabetes Clinical Research Centre, Plymouth", "city": "Plymouth", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "Salford Royal NHS Foundation Trust", "city": "Salford", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}]}, "referencesModule": {"references": [{"pmid": "28615149", "type": "DERIVED", "citation": "Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. doi: 10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11. Erratum In: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5. Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Site specific participant data will be made available to the site PIs later in 2017, after the main publications."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "493 participants where enrolled and consented. All participants entered a 3 month Run In phase with placebo. Participants who remained eligible were randomly assigned to receive metformin or placebo for 3 years. 65 participants where ineligible to be randomized.", "groups": [{"id": "FG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "FG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "219"}, {"groupId": "FG001", "numSubjects": "209"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "193"}, {"groupId": "FG001", "numSubjects": "194"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "15"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "BG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "55.2", "spread": "8.5"}, {"groupId": "BG001", "value": "55.8", "spread": "8.8"}, {"groupId": "BG002", "value": "55.5", "spread": "8.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "175"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "129"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "253"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "110"}]}]}, {"title": "Netherlands", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}]}, {"title": "Denmark", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "United Kingdom", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "217"}]}]}, {"title": "Australia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "62"}]}]}]}, {"title": "Diabetes Diagnosis Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33.4", "spread": "11"}, {"groupId": "BG001", "value": "34.3", "spread": "10.5"}, {"groupId": "BG002", "value": "33.85", "spread": "10.75"}]}]}]}, {"title": "Existing Cardiovascular Disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "52"}]}]}]}, {"title": "Baseline HbA1c", "paramType": "NUMBER", "unitOfMeasure": "mmol/mol", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "64.8"}, {"groupId": "BG001", "value": "64.7"}, {"groupId": "BG002", "value": "64.75"}]}]}]}, {"title": "Daily Insulin Dose", "paramType": "NUMBER", "unitOfMeasure": "units/kg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0.63"}, {"groupId": "BG001", "value": "0.68"}, {"groupId": "BG002", "value": "0.66"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "28.4", "spread": "4.5"}, {"groupId": "BG001", "value": "28.5", "spread": "4.1"}, {"groupId": "BG002", "value": "28.5", "spread": "4.3"}]}]}]}, {"title": "Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Systolic BP (mmHg)", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "130.5", "spread": "15"}, {"groupId": "BG001", "value": "128.5", "spread": "14.6"}, {"groupId": "BG002", "value": "129.5", "spread": "14.8"}]}]}]}, {"title": "Total Cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4", "spread": "0.88"}, {"groupId": "BG001", "value": "4", "spread": "0.93"}, {"groupId": "BG002", "value": "4", "spread": "0.91"}]}]}]}, {"title": "eGFR", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/min/1.73m2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "92.9", "spread": "20.9"}, {"groupId": "BG001", "value": "91.1", "spread": "21.6"}, {"groupId": "BG002", "value": "92", "spread": "21.3"}]}]}]}, {"title": "Diabetic Retinopathy", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "209"}, {"groupId": "BG002", "value": "428"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "109"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)", "description": "Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "0, 12 months, 24 months, 36 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.773", "spread": "0.14"}, {"groupId": "OG001", "value": "0.791", "spread": "0.183"}]}]}, {"title": "12 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.782", "spread": "0.147"}, {"groupId": "OG001", "value": "0.788", "spread": "0.174"}]}]}, {"title": "24 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.792", "spread": "0.145"}, {"groupId": "OG001", "value": "0.823", "spread": "0.187"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.793", "spread": "0.134"}, {"groupId": "OG001", "value": "0.820", "spread": "0.177"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c", "description": "Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "%units", "timeFrame": "Baseline, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.1", "spread": "0.9"}, {"groupId": "OG001", "value": "8.0", "spread": "0.8"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.1", "spread": "0.9"}, {"groupId": "OG001", "value": "8.1", "spread": "0.8"}]}]}]}, {"type": "SECONDARY", "title": "Change in LDL Cholesterol", "description": "mmol/L Centrally assayed at the University of Glasgow", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.23", "spread": "0.7"}, {"groupId": "OG001", "value": "2.25", "spread": "0.72"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.07", "spread": "0.83"}, {"groupId": "OG001", "value": "2.21", "spread": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Change in Estimated Glomerular Filtration Rate", "description": "Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml/min/1.73m2", "timeFrame": "Baseline, Year 1, Year 2, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.9", "spread": "20.9"}, {"groupId": "OG001", "value": "91.1", "spread": "21.6"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.1", "spread": "20.8"}, {"groupId": "OG001", "value": "87.2", "spread": "19.6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months", "description": "Two color 45\u00b0 field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "190"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Change in Weight", "description": "Measured at sites using calibrated weighing scales", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline, Year 1, Year 2, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.9", "spread": "15.4"}, {"groupId": "OG001", "value": "83.5", "spread": "13.7"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.0", "spread": "15.4"}, {"groupId": "OG001", "value": "83.2", "spread": "13.8"}]}]}]}, {"type": "SECONDARY", "title": "Change in Insulin Dose", "description": "Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units/kg", "timeFrame": "Baseline, Year 1, Year 2, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.36", "spread": "0.26"}, {"groupId": "OG001", "value": "0.68", "spread": "0.30"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.62", "spread": "0.26"}, {"groupId": "OG001", "value": "0.67", "spread": "0.30"}]}]}]}, {"type": "SECONDARY", "title": "Change in Endothelial Function", "description": "In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "RHI (Arbitrary units)", "timeFrame": "Baseline, Year 1, Year 3", "groups": [{"id": "OG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "194"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.28", "spread": "0.74"}, {"groupId": "OG001", "value": "2.24", "spread": "0.75"}]}]}, {"title": "36 Months", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.17", "spread": "0.69"}, {"groupId": "OG001", "value": "2.24", "spread": "0.73"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse event data collected from the date of consent until 30 days post last IMP dose, an average of 3 years.", "description": "Definition used same as clinical trials.gov", "eventGroups": [{"id": "EG000", "title": "Metformin", "description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily\n\nMetformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group", "deathsNumAffected": 5, "deathsNumAtRisk": 219, "seriousNumAffected": 34, "seriousNumAtRisk": 219, "otherNumAffected": 112, "otherNumAtRisk": 219}, {"id": "EG001", "title": "Placebo", "description": "Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo", "deathsNumAffected": 2, "deathsNumAtRisk": 209, "seriousNumAffected": 31, "seriousNumAtRisk": 209, "otherNumAffected": 52, "otherNumAtRisk": 209}], "seriousEvents": [{"term": "Metabolic and nutrition", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 209}]}, {"term": "Infections and Infestations", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 209}]}, {"term": "Neoplasms", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 209}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Gastrointestinal", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 209}]}, {"term": "Respiratory", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 209}]}, {"term": "Cardiac", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 209}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 209}]}, {"term": "Coronary artery bypass graft", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Musculoskeletal", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}]}, {"term": "Sudden Death", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Angiogram", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Circulatory collapse", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Blood and Lymphatic", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Immune System Disorder", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}]}, {"term": "hypoglycaemic coma", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "lung lobectomy", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "coronary stent insertion", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Amputation revision", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Surgery (unspecified)", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Coronary angioplasty", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Spinal fusion Surgery", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Aortic valve repair", "organSystem": "Surgical and medical procedures", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Blood Glucose Fluctuation", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Ischaemic Necrosis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Peripheral Ischaemia", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}], "otherEvents": [{"term": "Gastrointestinal", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 88, "numAffected": 88, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 18, "numAffected": 18, "numAtRisk": 209}]}, {"term": "Cardiovascular", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Neurological", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}]}, {"term": "Hypersensitivity to Metformin", "organSystem": "Product Issues", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 5, "numAffected": 1, "numAtRisk": 209}]}, {"term": "Opthalmic adverse events", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 219}, {"groupId": "EG001", "numEvents": 32, "numAffected": 32, "numAtRisk": 209}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Prof John Petrie", "organization": "University of Glasgow", "email": "John.Petrie@glasgow.ac.uk", "phone": "+44 141 330", "phoneExt": "3325"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2015-11-09", "uploadDate": "2018-09-12T03:35", "filename": "Prot_000.pdf", "size": 2150543}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-04-07", "uploadDate": "2018-09-12T03:44", "filename": "SAP_001.pdf", "size": 709303}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Diabetes Mellitus, Type 1", "relevance": "HIGH"}, {"id": "M14999", "name": "Retinal Diseases", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC11", "name": "Eye Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}